FDA approves non-combo hydrocodone product

Share this article:

Announced last Friday, Zohydro will become the first FDA-approved non-combination (not combined with analgesics like acetaminophen) and extended-release hydrocodone product.

The decision is particularly eyebrow-raising as only one day prior, the regulator issued a statement announcing it would aim to tighten the control of hydrocodone-combination products (like Vicodin) in an effort to reduce misuse and abuse by moving these products to Schedule II from Schedule III.

Schedule II drugs—part of the Controlled Substances Act—are classified as having a "high potential for abuse" and that abuse of those drugs could lead to "severe psychological or physiological dependence," under the Controlled Substances Act. Cocaine and methamphetamine, among others, are classified as Schedule II.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.